多囊卵巢综合征患者体成分对肝、肾功能和血脂的影响

doi:10.3969/j.issn.1006-7795.2024.04.010

首都医科大学学报 ›› 2024, Vol. 45 ›› Issue (4): 623-628.doi: 10.3969/j.issn.1006-7795.2024.04.010

• 更年期生殖内分泌与生育力保护 • 上一篇下一篇

多囊卵巢综合征患者体成分对肝、肾功能和血脂的影响

蒋玲玲¹, 阮祥燕^1，2*, 李妍秋¹, 张明珍¹, 王泽铖¹, 杨瑜¹, 刘莉莉¹, Alfred O. Mueck^1，2

1.首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科，北京 100026； 2.德国图宾根大学妇产医院妇女健康部与妇女健康研究中心，图宾根 D-72076

收稿日期:2024-04-30 出版日期:2024-08-21 发布日期:2024-07-08
通讯作者: 阮祥燕 E-mail:ruanxiangyan@ccmu.edu.cn
基金资助:
北京市医院管理中心“登峰”计划专项（DFL20181401）。

The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome

Jiang Lingling¹, Ruan Xiangyan^1,2*, Li Yanqiu¹, Zhang Mingzhen¹, Wang Zecheng^1, Yang Yu¹, Liu Lili¹, Alfred O. Mueck^1,2#br#

#br#

1.Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University/Beijing Maternal and Child Health Care Hospital, Beijing 100026, China; 2.Department of Women's Health, Research Centre for Women's Health and University Women's Hospital of Tuebingen, University Hospitals of Tuebingen, Tuebingen D-72076, Germany

Received:2024-04-30 Online:2024-08-21 Published:2024-07-08
Supported by:
This study was supported by the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20181401).

摘要/Abstract

摘要： 目的分析多囊卵巢综合征（polycystic ovary syndrome，PCOS）女性患者体成分对肝、肾功能和血脂的影响。方法本研究为横断面、病例对照研究，招募2020年10月至2023年12月于首都医科大学附属北京妇产医院内分泌科就诊的678例20~40岁的育龄期女性作为研究对象。根据2004年国际鹿特丹标准，将研究对象分为PCOS组（n=578）和对照组（n=100）。测量身高、体质量、腰围、臀围，并计算身体质量指数（body mass index,BMI）、测量体脂百分比(body fat percentage，BFP)、检测丙氨酸氨基转移酶（alanine transaminase,ALT）、门冬氨酸氨基转移酶（aspartate aminotransferase,AST）、肌酐（creatinine,Cre）、尿酸（uric acid, UA）、尿素氮（blood urea nitrogen,BUN）、总胆固醇（total cholesterol,TC）、三酰甘油（triglycerides,TG）、低密度脂蛋白胆固醇（low density lipoprotein-cholesterol,LDL-C）、高密度脂蛋白胆固醇（high density lipoprotein-cholesterol,HDL-C）、脂蛋白（a）［lipoprotein(a)，LP(a)］。并分析PCOS体成分对肝功能的影响。结果 PCOS组体质量、腰围、BMI均高于对照组，差异有统计学意义（P均＜0.05），PCOS组ALT、AST、UA也高于对照组，差异有统计学意义（P均＜0.05）；PCOS组BUN、Cre、HDL-C与对照组相比，差异无统计学意义。PCOS组BFP高于对照组，差异有统计学意义（P＜0.05），64.07%PCOS患者伴有超重或者肥胖。PCOS组转氨酶异常率高达12.8%，超重肥胖的PCOS患者转氨酶异常率高达17.86%，显著高于瘦型PCOS组和对照组（P均＜0.05）。关于血脂方面，PCOS患者TC、TG、LDL-C、LP（a）均显著高于对照组。结论 PCOS患者尤其是那些超重或肥胖者，面临更高的肝功能受损风险和血脂异常问题。因此，针对PCOS患者的管理应特别关注其体成分对肝、肾功能和血脂的影响，通过控制体质量、改善胰岛素抵抗、调节饮食和增加运动，有助于提高PCOS患者的整体健康状况和远期生命质量。

关键词: 多囊卵巢综合征, 体成分, 肝功能, 肾功能, 血脂水平

Abstract: Objective To analyze the impact of body composition on liver and kidney function and blood lipids in women with polycystic ovary syndrome (PCOS).Methods This cross-sectional case-control study recruited 678 women aged 20-40 years from the Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, between October 2020 and December 2023. According to the 2004 international Rotterdam criteria, participants were divided into a PCOS group (n=578) and a control group (n=100). Height, weight, waist circumference, and hip circumference were measured, and body mass index (BMI) was calculated. Body fat percentage (BFP) was measured. Alanine transaminase (ALT), aspartate aminotransferase (AST), creatinine (Cre), uric acid (UA), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and lipoprotein(a) ［LP(a)］ levels were detected. The impact of body composition on liver function in PCOS was analyzed.Results PCOS group had significantly higher body weight, waist circumference, and BMI than the control group (all P<0.05). ALT, AST, and UA levels in the PCOS group were significantly higher than those in the control group (all P<0.05). There were no statistically significant differences in BUN, Cre, and HDL-C between the PCOS and control groups. The body fat percentage in the PCOS group was significantly higher than that in the control group (P<0.05), with 64.07% of PCOS patients being overweight or obese. The abnormal transaminase rate in the PCOS group was 12.8%, while that in overweight and obese PCOS patients was 17.86%. The abnormal transaminase rate in overweight and obese PCOS patients was significantly higher than that in lean PCOS patients and the control group (both P<0.05). Regarding blood lipids, PCOS patients had significantly higher TC, TG, LDL-C, and LP(a) levels than the control group.Conclusions Patients with PCOS, especially those who are overweight or obese, face higher risk of liver dysfunction and dyslipidemia. Therefore, the management of PCOS patients should pay special attention to the impact of body composition on liver and kidney function as well as lipid levels. The overall health and long-term quality of life of PCOS patients can be improved, through controlling weight, improving insulin resistance, regulating diet, and increasing physical activity.

Key words: polycystic ovary syndrome, body composition, liver function, kidney function, blood lipid levels

中图分类号:

R711

蒋玲玲, 阮祥燕, 李妍秋, 张明珍, 王泽铖, 杨瑜, 刘莉莉, Alfred O. Mueck. 多囊卵巢综合征患者体成分对肝、肾功能和血脂的影响[J]. 首都医科大学学报, 2024, 45(4): 623-628.

Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Yang Yu , Liu Lili, Alfred O. Mueck. The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2024, 45(4): 623-628.

参考文献

［1］ Azziz R, Carmina E, Chen Z J, et al. Polycystic ovary syndrome［J］. Nat Rev Dis Primers, 2016, 2: 16057.
［2］ Yang R, Li Q, Zhou Z H, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade［J］. Lancet Reg Health West Pac, 2022, 25: 100494.
［3］ Walker K, Decherney A H, Saunders R. Menstrual dysfunction in PCOS［J］. Clin Obstet Gynecol, 2021, 64(1): 119-125.
［4］ Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey［J］. Int J Adolesc Med Health, 2021, 33(6): 367-373.
［5］ Zhang J H, Hu J, Zhang C X, et al. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease［J］. Exp Ther Med, 2018, 15(5): 4259-4264.
［6］ Li A A, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease［J］. Gut Liver, 2020, 14(2): 168-178.
［7］ Holmer M, Melum E, Isoniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries［J］. Liver Int, 2018, 38(11): 2082-2090.
［8］ Zhang J, Xu J H, Qu Q Q, et al. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a Meta-analysis of cohort studies［J］. Front Cardiovasc Med, 2020, 7: 552421.
［9］ Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome［J］. Fertil Steril, 2004, 81(1): 19-25.
［10］中国医疗保健国际交流促进会营养与代谢管理分会,中国营养学会临床营养分会,中华医学会糖尿病学分会,等. 中国超重/肥胖医学营养治疗指南(2021)［J］. 中国医学前沿杂志: 电子版, 2021, 13(11): 1-55.
［11］ Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when?［J］. Endocrinol Metab Clin North Am, 2021, 50(1): 11-23.
［12］ Khan K A, Stas S, Kurukulasuriya L R. Polycystic ovarian syndrome［J］. J Cardiometab Syndr, 2006, 1(2): 125-130; quiz 131-132.
［13］ Wang D X, Nan N, Bing H, et al. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome［J］. Front Endocrinol, 2023, 14: 1241734.
［14］ Vrbikova J, Fanta M, Cibula D, et al. Impaired glucose metabolism in women with polycystic ovary syndrome［J］. Gynecol Obstet Invest, 2009, 68(3): 186-190.
［15］ Yu J, Zhou Y L, Ding J, et al. Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome［J］. Front Endocrinol, 2022, 13: 970733.
［16］ Stener-Victorin E, Baghaei F, Holm G, et al. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial［J］. Fertil Steril, 2012, 97(2): 501-508.
［17］ Yousuf S D, Ganie M A, Jeelani S, et al. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor Ⅷ among women with polycystic ovary syndrome: an observational pilot study［J］. Indian J Med Res, 2018, 148(Suppl): S151-S155.
［18］ Kelley C E, Brown A J, Diehl A M, et al. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome［J］. World J Gastroenterol, 2014, 20(39): 14172-14184.
［19］ Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?［J］. Endocrine, 2016, 51(2): 211-221.
［20］ Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, et al. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis［J］. Hepat Mon, 2014, 14(11): e23235.
［21］ Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases［J］. Hepatology, 2018, 67(1): 328-357.
［22］ Frias-Toral E, Garcia-Velasquez E, De Los A C M, et al. Polycystic ovary syndrome and obesity: clinical aspects and nutritional management［J］. Minerva Endocrinol, 2022, 47(2): 215-241.
［23］ Bizoń A, Franik G, Niepsuj J, et al. The associations between sex hormones and lipid profiles in serum of women with different phenotypes of polycystic ovary syndrome［J］. J Clin Med, 2021, 10(17): 3941.
［24］ Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome［J］. Dig Liver Dis, 2015, 47(3): 181-190.
［25］ Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?［J］. J Hepatol, 2018, 68(2): 335-352.

[1]	赵越, 阮祥燕, 王月姣, 马郡, 金婧. 女性雄性激素质谱多指标检测在多囊卵巢综合征诊断中的应用[J]. 首都医科大学学报, 2024, 45(4): 602-608.
[2]	田玄玄, 阮祥燕, 金婧, 鞠蕊, 杜娟, 程姣姣, 杨瑜. 多囊卵巢综合征患者不同临床表型的性功能分析[J]. 首都医科大学学报, 2024, 45(4): 616-622.
[3]	张明珍, 阮祥燕, 闵敏, Alfred O.Mueck. 奥利司他综合干预对超重或肥胖多囊卵巢综合征患者脂蛋白（a）、糖脂代谢及肝、肾功能的影响[J]. 首都医科大学学报, 2023, 44(4): 544-549.
[4]	田玄玄, 阮祥燕, 金婧, 王娟, 程姣姣. 多囊卵巢综合征患者对生活方式干预获益的认知度调查[J]. 首都医科大学学报, 2023, 44(4): 555-560.

多囊卵巢综合征患者体成分对肝、肾功能和血脂的影响

The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价